# FDA Type: organization Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/fda-organization Canonical HTML page: https://getfinancebrief.com/entity/fda-organization ## Timeline - **2026-03-25**: Clinical Data Release — Early data for FSHD and DM1 therapies reported by STAT and Endpoints News. - **2026-03-25**: Options Surge — Traders purchase large volumes of call options following the clinical updates. - **2026-03-13**: Price Target Update — Brokerages adjust targets, including a raise to $9.00 by some analysts. - **2026-03-12**: BofA Target Increase — Bank of America raises price target based on pharmaceutical and MedTech pipeline strength. - **2026-03-12**: Q4 2025 Earnings — Both Mineralys and Vuzix report year-end financial results and 2026 guidance. - **2026-03-10**: Institutional Rebalancing — Richard Bernstein Advisors and Rathbones Group PLC report reduced holdings in JNJ. - **2026-03-09**: FDA NDA Acceptance — FDA formally accepts Mineralys Therapeutics' application for Lorundrostat. - **2026-03-07**: Fast-Track Approval — FDA approves Tecvayli-Darzalex combination for blood cancer treatment. - **2026-03-05**: FDA Approval & 12-Month High — JNJ receives FDA approval for multiple myeloma combo and stock hits a yearly peak. - **2026-02-26**: Q4 2025 Earnings — Company reports results and provides 2026 guidance, signaling continued remediation efforts. - **2026-02-18**: FDA U-Turn — Moderna confirms the FDA has resolved the dispute and will now consider the vaccine for approval. - **2026-02-15**: Public Dispute — Moderna and administration officials engage in a public disagreement over the regulatory path forward. - **2026-02-10**: Initial Rejection — Reports emerge that the FDA vaccine chief overruled scientists to reject Moderna's flu shot filing. - **2026-01-12**: Financial Results — Sarepta files results of operations and financial condition with the SEC. - **2026 (estimated)**: Projected Restart — Target window for the commercial re-launch of SurgiMend and PriMatrix products. ## Recent coverage (12 stories) ### Axsome Revenue Doubles to $617M; 3 Biotechs Returned 230% vs. S&P 9% in H1 2026-07-07 06:57:49 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 A trio of biotech stocks generated staggering H1 2026 returns, with Revolution Medicines leading at +230%. Axsome Therapeutics' revenue more than doubled to $617.1 million, underscoring a market rotation into catalyst-driven, high-growth healthcare plays amid macro uncertainty. Full story: https://getfinancebrief.com/story/biotech-beats-sp500-financial-analysis ### Bullish Options Surge in Sarepta Therapeutics Amid Promising Rare Disease Data 2026-03-25 19:55:52 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Traders have flooded Sarepta Therapeutics with call options following positive early-stage data for its RNA-based rare disease therapies. This surge in bullish sentiment suggests high market confidence in the company's clinical pipeline expansion beyond its core Duchenne muscular dystrophy franchise. Full story: https://getfinancebrief.com/story/sarepta-therapeutics-options-volume-surge-2026 ### Kestra Medical Reports 63% Revenue Surge on Assure System Adoption 2026-03-18 00:41:09 · Sentiment: Bullish · Impact: 6/10 · Sources: 2 Kestra Medical (KMTS) delivered a strong Q3 2026 performance, highlighted by a 63% year-over-year revenue increase and the ninth consecutive quarter of gross margin expansion. While net losses widened to $34.2 million due to aggressive sales force expansion, the company secured critical access to the VA Federal Supply Schedule and expanded its Florida Medicaid footprint. Full story: https://getfinancebrief.com/story/kestra-medical-q3-2026-earnings-analysis ### Tech and Biotech Pivot: LivePerson, Inovio, and Bakkt Realign for 2026 Growth 2026-03-18 00:33:36 · Sentiment: Neutral · Impact: 6/10 · Sources: 3 LivePerson, Inovio, and Bakkt reported Q4 2025 results highlighting strategic transitions toward AI integration, regulatory milestones, and balance sheet restructuring. While LivePerson capitalizes on generative AI adoption and Inovio nears a critical FDA PDUFA date, Bakkt has streamlined its capital structure to focus on institutional crypto services. Full story: https://getfinancebrief.com/story/lpsn-ino-bkkt-q4-2025-earnings-analysis ### Abeona and Consolidated Water Set for FY 2025 Results Amid Sector Shifts 2026-03-16 18:21:48 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Abeona Therapeutics and Consolidated Water are preparing to report full-year 2025 financial results, highlighting contrasting paths in the biotech and utility sectors. While Abeona faces critical regulatory milestones for its gene therapy pipeline, Consolidated Water continues to leverage infrastructure expansion to drive steady revenue growth. Full story: https://getfinancebrief.com/story/abeona-consolidated-water-fy2025-earnings-preview ### Josh Brown: Biotech Growth Emerges as Ultimate Hedge Against AI Disruption 2026-03-13 05:24:14 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Josh Brown argues that biotech growth stocks are uniquely positioned to withstand the disruption risks currently de-rating the software and services sectors. By leveraging AI to accelerate discovery while maintaining regulatory and patent moats, the sector offers a rare combination of high growth and structural stability. Full story: https://getfinancebrief.com/story/josh-brown-biotech-disruption-immunity ### Mineralys and Vuzix Q4 Earnings: Biotech Milestones vs. AR Scaling 2026-03-12 23:34:01 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Mineralys Therapeutics secured a major regulatory win with FDA acceptance of its Lorundrostat NDA, while Vuzix continues to navigate the transition from pilot programs to enterprise-scale AR deployments. Full story: https://getfinancebrief.com/story/mineralys-vuzix-q4-2025-earnings-analysis ### BofA Bullish on Johnson & Johnson as Pipeline Momentum Drives Target Hike 2026-03-12 08:12:14 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Bank of America has raised its price target for Johnson & Johnson, citing robust growth in the company's pharmaceutical and MedTech pipelines. The upgrade follows a series of FDA approvals and a strategic pivot toward high-margin innovative medicine after the Kenvue spinoff. Full story: https://getfinancebrief.com/story/bofa-raises-jnj-price-target-pipeline-growth ### Biotech Weekly: Ascendis Gains FDA Nod as Aardvark Pauses Lead HERO Trial 2026-03-06 16:58:06 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 The biotech sector experienced a week of high-stakes regulatory and clinical developments, headlined by a key FDA approval for Ascendis Pharma. Meanwhile, Aardvark Therapeutics faced a setback with its HERO trial on hold, and Theravance Biopharma announced strategic job cuts to preserve capital. Full story: https://getfinancebrief.com/story/biotech-weekly-asnd-fda-approval-aardvark-trial-hold ### Integra LifeSciences Faces Market Pressure as Turnaround Timeline Extends 2026-02-26 22:45:09 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Integra LifeSciences (IART) shares faced downward pressure following its Q4 2025 earnings call, as management detailed an extended timeline for its Boston facility restart and the ongoing costs of its Quality Excellence Program. While the company provided its first full-year 2026 guidance, investor caution remains high regarding the path to normalized growth and product re-launches. Full story: https://getfinancebrief.com/story/integra-lifesciences-iart-earnings-analysis-2026 ### FDA Reverses Stance on Moderna’s mRNA Flu Shot, Clearing Path for Review 2026-02-18 21:43:09 · Sentiment: Bullish · Impact: 7/10 · Sources: 3 The U.S. Food and Drug Administration has unexpectedly reversed its previous position, agreeing to review Moderna’s mRNA-based influenza vaccine candidate. This regulatory pivot marks a critical victory for Moderna as it seeks to diversify its portfolio beyond COVID-19 and challenge the traditional seasonal flu market. Full story: https://getfinancebrief.com/story/fda-reversal-moderna-mrna-flu-shot-review ### FDA Reverses Course on Moderna mRNA Flu Shot After Controversial Rejection 2026-02-18 18:57:55 · Sentiment: Bullish · Impact: 8/10 · Sources: 6 The U.S. Food and Drug Administration has agreed to review Moderna’s experimental mRNA flu vaccine, reversing a previous decision that sparked a public dispute. The initial rejection, which reportedly saw political appointees overrule career scientists, had briefly cast doubt on the regulatory path for the company's post-COVID pipeline. Full story: https://getfinancebrief.com/story/fda-moderna-flu-shot-reversal --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.